MedTrace Logo

Safety Study of Live Attenuated Influenza Vaccine, CodaVax

NCT03926416 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2020-07-23

No results posted yet for this study

Summary

This study is being conducted to assess the safety, tolerability, and immunogenicity of the CodaVax-H1N1 influenza vaccine as compared to active and placebo controls when administered to healthy adults.

Conditions

Interventions

BIOLOGICAL

CodaVax-H1N1

Live-attenuated vaccine against influenza A H1N1, A/California/07/2009

BIOLOGICAL

Fluzone quadrivalent

Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine

Sponsors & Collaborators

  • Codagenix, Inc

    lead INDUSTRY

Principal Investigators

  • Paul Griffin, MD · Q-Pharm Pty Limited

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-21
Primary Completion
2018-05-29
Completion
2018-09-14
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03926416 on ClinicalTrials.gov